

First encouraging results for the clinical trial on osteoarthritis

DMS Biotech, a division of **Diagnostic Medical Systems Group (Euronext Paris - FR0012202497 - DGM)** dedicated to biotechnologies, is conducting a progress report on the ongoing clinical trial (on humans) for the use of a fat cell preparation in the treatment of osteoarthritis.

This clinical trial, involving 40 patients with knee osteoarthritis, aims to evaluate the efficacy and safety of the injection of an adipose tissue preparation, in comparison with hyaluronic acid, in the treatment of this pathology. Osteoarthritis, a joint disease leading to the destruction of cartilage, affects 65% of over 65's and 80% of over 80's.

The patients received an injection of adipose tissue or hyaluronic acid, and were then reviewed at 1 week, 1 month, 3 months and 6 months after the injection. Follow-up visits at 12 months are currently underway. After consulting the doctors carrying out the study, they decided to communicate the intermediate results (6 months post-injection) at the same time as the final results (12 months post-injection), during the 2nd quarter of 2019.

The first results, however, are particularly encouraging: the treatment technique is rapid, minimally invasive and appreciated by patients. The effectiveness of treatment (reduction of pain, improvement of function and quality of life) and the duration of its effect (maintenance of the effect at one year, for the first patients seen in consultations 12 months post-injection) appear superior to hyaluronic acid.

Pending the detailed publication of the final results, given the interest of many doctors for the subject, scientific sessions will be organized by various distributors of Adip'Sculpt lipofilling devices (surgical autograft technique using adipose tissue). Two workshops have already been organized by High Tech Medical (Australian distributor) in Sydney and Melbourne in December 2018.

As a reminder, the study on animals (dogs) finalized in 2018, aimed at evaluating the efficacy and safety of this fat cell preparation in the treatment of canine osteoarthritis, had already shown a very significant decrease in pain and lameness 6 months after injection. No adverse effects were seen after treatment.

This technology, which uses the anti-inflammatory and regenerative properties of adipose tissue, offers new perspectives for the treatment of osteoarthritis. Indeed, if the final results confirm the maintenance of the effect one year after treatment, and without it being necessary to repeat the injections, it could represent an alternative to injections of hyaluronic acids (recently repealed in France in 2017) and possibly delay or replace the use of a prosthesis.



About DMS Group

DMS Group is made up of companies with high potential for innovation. Historically focused on the medical imaging industry, activity is gradually developing in new directions. By investing in the future and betting on research, DMS Group hopes to bring the solutions of tomorrow.

- **DMS Imaging** specializes in high technology for medical diagnostics and is today the French leader in the development, design and manufacture of imaging systems dedicated to radiology, bone densitometry and 3D modeling and posturology.
- **DMS Wellness** brings together activities dedicated to the health and well-being sector, aimed at specialists in physiotherapy, beauty, aesthetics and sport.
- **DMS Biotech** supports the group's development strategy in the field of biotechnologies, and in particular technologies for the treatment of osteoarthritis and regenerative medicine based on the injection of adipose stem cells.

DMS Group is present on all continents through a network of more than 140 national distributors, subsidiaries and joint ventures. In 2017, DMS Group achieved consolidated sales of € 27.1 million. DMS Group is listed on Euronext Paris (ISIN: FR0012202497 - mnemo: DGM).

More information on www.dms.com.

RECEIVE FREE OF THE DMS GROUP FINANCIAL INFORMATION BY E-MAIL BY REGISTERING ON WWW.ACTUSNEWS.COM.

Contacts

DMS Group

Jean-Paul ANSEL

CEO

04 67 50 49 00

ACTUS FINANCE

Mathieu OMNES

Investor Relations

01 53 67 36 92

Alexandra PRISA

Press relations

01 53 67 36 90